Revvity tops Q1 estimates and unveils plans to exit China immunodiagnostics

The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue

Boston Scientific surges into 2026 with double-digit sales growth & record quarterly profit jump

Growth was broad-based across segments

INST scientists develop glowing nanosensor for rapid nicotine, cotinine detection

he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers

Corona Remedies acquires antiseptic brand Wokadine from Dr Reddy’s to enter Iodine market

This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility

Lonza to sell capsules & health ingredients business for $3 billion in major strategic shift

Merck delivers resilient 2025 performance despite global headwinds

Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results

Fortis Healthcare posts strong Q3 FY26 growth; revenues up 17.5% YoY

The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore

Zydus Lifesciences reports strong Q3 & 9M FY26 growth

Revenue from operations surged 30% year-on-year to Rs. 68,645 million

Revvity posts higher Q4 earnings, lifts 2026 outlook as diagnostics strength offsets margin pressure

Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come

Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth

Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model